Volume 11, Issue 41 (11-2020)
NCMBJ 2020, 11(41): 17-28 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Investigation of Molecular Mechanisms in Inhibiting the Function of Spike, Main Protease and Papain Like Protease in Coronavirus Using Simulation and Docking. NCMBJ 2020; 11 (41) :17-28
URL: http://ncmbjpiau.ir/article-1-1337-en.html
URL: http://ncmbjpiau.ir/article-1-1337-en.html
Abstract: (2862 Views)
Aim and Backgrounds: Coronavirus is the causative agent of COVID-19 infectious pneumonia, which was introduced by the World Health Organization in 2020 as a global epidemic. Due to the fact that its inhibitory mechanisms have not been well understood so far, in this article we decided to investigate the inhibitory mechanisms of Spike, Main Protease and Papain-like protease proteins in the coronavirus.
Materials and methods: In the present study, all calculations were performed by AutoDock 4.2 (2013), AutoDockTools 4.2 (2013) and Cluspro2.0 (2017). Lamarck's genetic algorithm was used to search for protein levels, and 200 were performed in each of the docking models. Finally, the interaction of protein binding and inhibitor compounds and hydrogen and hydrophobic binding was calculated by Poseview and DIMPLOT software.
Results: The interaction study showed that the amino acids His163, His164, Gln189, Glu166, Cys145 and Phe140 play a key role in the inhibitory interaction of GC-376 with Mpro protein due to hydrogen bonds. Also, the study of the binding energy of the inhibitor compound to the protein shows that this compound is attached to the inhibitor with a binding energy of -6.36 kcal / mol. The docking results of PLpro complex showed that the amino acids Tyr268, Gln269, and Asp164 play a key role in the interaction of GRL0617 inhibitor with PLpro protein due to hydrogen bonds and the binding energy of the inhibitor compound to PLpro protein was -9.69. Finally, the study of the interactions of Spike protein and LCB1 peptide using Cluspro and DIMPLOT software showed that there are several hydrophobic and polar interactions between different amino acids of these two compounds, the most important of which can be He noted the interaction of the amino acid Tyr489 in the Spike protein with the amino acids Leu6 and Gln7 in the inhibitory peptide.
Conclusion: The results of this study showed that the inhibitory compounds presented in this article can well inhibit vital proteins important in coronavirus due to polar and hydrophobic interactions.
Materials and methods: In the present study, all calculations were performed by AutoDock 4.2 (2013), AutoDockTools 4.2 (2013) and Cluspro2.0 (2017). Lamarck's genetic algorithm was used to search for protein levels, and 200 were performed in each of the docking models. Finally, the interaction of protein binding and inhibitor compounds and hydrogen and hydrophobic binding was calculated by Poseview and DIMPLOT software.
Results: The interaction study showed that the amino acids His163, His164, Gln189, Glu166, Cys145 and Phe140 play a key role in the inhibitory interaction of GC-376 with Mpro protein due to hydrogen bonds. Also, the study of the binding energy of the inhibitor compound to the protein shows that this compound is attached to the inhibitor with a binding energy of -6.36 kcal / mol. The docking results of PLpro complex showed that the amino acids Tyr268, Gln269, and Asp164 play a key role in the interaction of GRL0617 inhibitor with PLpro protein due to hydrogen bonds and the binding energy of the inhibitor compound to PLpro protein was -9.69. Finally, the study of the interactions of Spike protein and LCB1 peptide using Cluspro and DIMPLOT software showed that there are several hydrophobic and polar interactions between different amino acids of these two compounds, the most important of which can be He noted the interaction of the amino acid Tyr489 in the Spike protein with the amino acids Leu6 and Gln7 in the inhibitory peptide.
Conclusion: The results of this study showed that the inhibitory compounds presented in this article can well inhibit vital proteins important in coronavirus due to polar and hydrophobic interactions.
Keywords: Coronavirus, the main Protease protein, Spike protein, Papain like protease protein., IAU science.
Type of Study: Research Article |
Subject:
Cellular and molecular
Received: 2021/01/1 | Accepted: 2020/11/30 | Published: 2020/11/30
Received: 2021/01/1 | Accepted: 2020/11/30 | Published: 2020/11/30
References
1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine. 2020.
2. Tavakoli A, Vahdat K, Keshavarz M. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. ISMJ. 2020;22(6):432-50.
3. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi. 2020;41(2):145.
4. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020:P7-P8.
5. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.
6. Chu DK, Pan Y, Cheng SM, Hui KP, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clinical chemistry. 2020;66(4):549-55.
7. Loeffelholz MJ, Tang Y-W. Laboratory diagnosis of emerging human coronavirus infections–the state of the art. Emerging microbes & infections. 2020;9(1):747-56.
8. Goo J, Jeong Y, Park Y-S, Yang E, Jung D-I, Rho S, et al. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein. Virus Research. 2020;278:197863.
9. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science. 2020;12(1):1-6.
10. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah N, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral research. 2020;176:104742.
11. McCallum M, Walls AC, Bowen JE, Corti D, Veesler D. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nature Structural & Molecular Biology. 2020:1-8.
12. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging microbes & infections. 2020;9(1):382-5.
13. Elfiky A, Ibrahim NS. Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV). 2020.
14. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. Journal of virology. 2004;78(24):13600-12.
15. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. The FEBS journal. 2014;281(18):4085-96.
16. Zhao Q, Li S, Xue F, Zou Y, Chen C, Bartlam M, et al. Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. Journal of virology. 2008;82(17):8647-55.
17. Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-Ldrissi M, Bouachrine M. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations. Journal of Biomolecular Structure and Dynamics. 2020:1-9.
18. Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors–an in silico docking and molecular dynamics simulation study. Journal of Biomolecular Structure and Dynamics. 2020:1-13.
19. Morris G, Goodsell D, Pique M, Lindstrom W, Huey R, Forli S, et al. AutoDock 4.2 with AutoDockTools. 2009.
20. Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. bioRxiv. 2020.
21. Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020.
22. Gao X, Qin B, Chen P, Zhu K, Hou P, Wojdyla JA, et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharmaceutica Sinica B. 2020.
23. Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein–protein docking. Nature protocols. 2017;12(2):255.
24. Stierand K, Rarey M. PoseView--molecular interaction patterns at a glance. Journal of cheminformatics. 2010;2(1):1-.
25. Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331-5.
26. Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas SJ, et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv. 2020.
27. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020:1-5.
28. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target. EXCLI journal. 2020;19:400.
29. Alamri MA, ul Qamar MT, Mirza MU, Alqahtani SM, Froeyen M, Chen L-L. Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches. Journal of Pharmaceutical Analysis. 2020.
30. Guillén J, Pérez-Berná AJ, Moreno MR, Villalaín J. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism. Journal of virology. 2005;79(3):1743-52.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
